✦ LIBER ✦

CHARACTERIZATION OF RWJ-351647, A NOVEL NONPEPTIDE VASOPRESSIN V2 RECEPTOR ANTAGONIST

✍ Scribed by Joseph W Gunnet; Jay M Matthews; Bruce E Maryanoff; Lawrence De Garavilla; Patricia Andrade-Gordon; Bruce Damiano; William Hageman; Richard Look; Paul Stahle; Anthony J Streeter; Pamela G Wines; Keith T Demarest

Book ID: 108937782
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 154 KB
Volume: 33
Category: Article
ISSN: 0305-1870
DOI: 10.1111/j.1440-1681.2006.04369.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacological characterization of YM08

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

✍ A. Tahara; M. Saito; T. Sugimoto; Y. Tomura; K. Wada; T. Kusayama; J. Tsukada; N 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 83 KB

Vascular Effects of RWJ-676070, a Select

Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist

✍ Coltamai, L; Bucher, M; Maillard, MP; Shukla, U; Bohidar, N; Haskell, L; Bertels 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB

ChemInform Abstract: Synthesis and Chara

ChemInform Abstract: Synthesis and Characterization of Orally Active Nonpeptide Vasopressin V2 Receptor Antagonists.

✍ Takehiko Ohkawa; Tatsuya Zenkoh; Masayuki Tomita; Naomi Hosogai; Keiji Hemmi; Hi 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 31 KB 👁 2 views

Characterization of a novel nonpeptide v

Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes

✍ Shigeki Nakamura; Yoshitaka Yamamura; Shuji Itoh; Takahiro Hirano; Kenji Tsujima 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 169 KB

Sustained aquaretic effect of the V2-AVP

Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention

✍ Josefa Ros; Guillermo Fernández-Varo; Javier Muñoz-Luque; Vicente Arroyo; Juan R 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 177 KB

Oral V2 receptor antagonist (RWJ-351647)

Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study

✍ P. J. THULUVATH; A. MAHESHWARI; F. WONG; H. W. YOO; R. W. SCHRIER; C. PARIKH; S. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 695 KB